Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Sino Biopharmaceutical Limited is a prominent healthcare company that focuses on the research, development, manufacturing, and commercialization of pharmaceutical products. With a comprehensive portfolio, the company delivers a variety of offerings, including innovative drugs, modern Chinese medicines, and chemical and biological medicines. Its operations significantly impact sectors such as oncology, cardiovascular disease, hepatitis treatments, and orthopedics, making it a key player in the pharmaceutical industry. Renowned for its research and development capabilities, Sino Biopharmaceutical Limited emphasizes technological advancements and innovation, hence continuously enhancing its competitive edge in the market. The company's presence primarily in Asian markets also contributes to the development of healthcare systems within the region. Being a part of the Hong Kong Stock Exchange, Sino Biopharmaceutical Limited plays a pivotal role by contributing to the growth and stability of the pharmaceutical sector within the industry's ecosystem. It supports the advancement of healthcare solutions, thereby meeting the increasing demand for specialized and effective medical treatments across its operating regions.
¥0.60
+¥0.00 (+0.00%)
EOD Jun 25, 2026 · Twelve Data
21.67% operating margin is above average. ROIC at 9.55%. Note that capital returns lag the margin, the business may be capital-intensive despite high margins.
Revenue grew 10.3%, still solid.
At 32x earnings, the current multiple leaves limited room for execution misses or growth deceleration.
31.5x earnings, 22.1x FCF. Not cheap, the quality is already reflected in the price. Upside from here requires either margin expansion or growth re-acceleration, not just continuation.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
¥31.83B
▲ +10.3% YoY
Net Income (TTM)
¥5.31B
▼ -16.5% YoY
Op. Margin
21.67%
▼ -0.3pp YoY
ROIC
9.55%
▼ -1.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
¥7.59B
▲ +45.4% YoY
Op. Cash Flow (TTM)
¥8.78B
▲ +42.8% YoY
Net Debt
-¥6.89B
Net Cash Position
Cash & Equiv.
¥22.96B
3Y CAGR: +6.9%
3Y CAGR: +18.5%
Continue Research
At a P/E of 31.5 and a price-to-free-cash-flow of 22.1, Sino Biopharmaceutical (SBMFF) trades below a two-stage DCF intrinsic value of about CNY 7.99 per share, so at CNY 0.60 the stock looks undervalued (1,226.4% below estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Sino Biopharmaceutical scores 74/100 on Intrinsiqq's quality scorecard (a solid business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. It currently yields about 0.9%; see dividend safety for coverage and history. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about CNY 7.99 per share for SBMFF, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around CNY 5.99. At today's CNY 0.60, that puts the stock about 1,226.4% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Sino Biopharmaceutical scores 74 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which makes it a solid business on these measures. Recent fundamentals include a 21.7% operating margin and a 9.5% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Yes, Sino Biopharmaceutical pays a regular dividend of about CNY 0.04 per share per year (typically in quarterly installments), a yield of roughly 0.9% at the current price. That is a payout ratio of about 28.3% of earnings, so the dividend is amply covered by earnings. Sino Biopharmaceutical has grown the dividend at roughly 12.5% a year over the past few years. A low headline yield is not the same as a weak dividend: what matters is how well earnings and free cash flow cover the payout and whether it is growing, not the percentage alone. For SBMFF's full payout history, growth streak and dividend-safety score, see the dividends tab.
That depends on valuation and quality together, not either alone. SBMFF currently trades below its estimated intrinsic value and scores 74/100 on quality (solid). It also yields about 0.9%. A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.